Atreca Inc.

2.40+0.1300+5.73%Vol 105.18K1Y Perf -60.45%
Aug 11th, 2022 16:00 DELAYED
BID2.33 ASK2.44
Open2.29 Previous Close2.27
Pre-Market- After-Market2.44
 - -  0.04 1.67%
Target Price
15.71 
Analyst Rating
Strong Buy 1.00
Potential %
554.58 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
16.21 
Earnings Rating
Market Cap92.62M 
Earnings Date
10th Aug 2022
Alpha-0.03 Standard Deviation0.28
Beta0.62 

Today's Price Range

2.232.41

52W Range

1.517.00

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
-5.88%
1 Month
7.14%
3 Months
47.24%
6 Months
40.35%
1 Year
-60.45%
3 Years
-79.17%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BCEL2.400.13005.73
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.70-0.72-2.86
Q01 2022-0.78-0.6516.67
Q04 2021-0.75-0.79-5.33
Q03 2021-0.75-0.741.33
Q02 2021-0.71-0.72-1.41
Q01 2021-0.65-0.70-7.69
Q04 2020-0.63-0.630.00
Q03 2020-0.60-0.66-10.00
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.70
Estimates Count7
EPS Growth Next 5 Years %-
Volume Overview
Volume105.18K
Shares Outstanding38.59K
Shares Float27.28M
Trades Count905
Dollar Volume244.50K
Avg. Volume215.39K
Avg. Weekly Volume179.42K
Avg. Monthly Volume176.13K
Avg. Quarterly Volume290.63K

Atreca Inc. (NASDAQ: BCEL) stock closed at 2.4 per share at the end of the most recent trading day (a 5.73% change compared to the prior day closing price) with a volume of 105.18K shares and market capitalization of 92.62M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 128 people. Atreca Inc. CEO is John A. Orwin.

The one-year performance of Atreca Inc. stock is -60.45%, while year-to-date (YTD) performance is -20.79%. BCEL stock has a five-year performance of %. Its 52-week range is between 1.51 and 7, which gives BCEL stock a 52-week price range ratio of 16.21%

Atreca Inc. currently has a PE ratio of -0.70, a price-to-book (PB) ratio of 0.58, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -47.05%, a ROC of -50.63% and a ROE of -62.52%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Atreca Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.70 for the next earnings report. Atreca Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Atreca Inc. is Strong Buy (1), with a target price of $15.71, which is +554.58% compared to the current price. The earnings rating for Atreca Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Atreca Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Atreca Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 11.93, ATR14 : 0.22, CCI20 : 101.53, Chaikin Money Flow : 0.05, MACD : 0.08, Money Flow Index : 61.95, ROC : 25.00, RSI : 48.27, STOCH (14,3) : 72.22, STOCH RSI : 0.75, UO : 58.40, Williams %R : -27.78), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Atreca Inc. in the last 12-months were: Tito A. Serafini (Sold 75 000 shares of value $377 807 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (100.00 %)
7 (100.00 %)
7 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Atreca Inc.

Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.

CEO: John A. Orwin

Telephone: +1 650 595-2595

Address: 450 East Jamie Court, South San Francisco 94080, CA, US

Number of employees: 128

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

66%34%

Bearish Bullish

60%40%

TipRanks News for BCEL

Tue, 09 Aug 2022 00:40 GMT Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS), Atreca (BCEL) and CSL (OtherCMXHF)

- TipRanks. All rights reserved.

Sun, 06 Mar 2022 14:10 GMT Atreca (BCEL) Gets a Buy Rating from Stifel Nicolaus

- TipRanks. All rights reserved.

News

Stocktwits